Continuous therapy versus fixed duration of therapy in patients with newly diagnosed multiple myeloma

Journal of Clinical Oncology

Volumn 33, Issue 30, 2015, Pages 3459-3466

  Palumbo, Antonio ^a   Gay, Francesca ^a   Cavallo, Federica ^a   Raimondo, Francesco D ^d   Larocca, Alessandra ^a   Hardan, Izhar ⁿ   Nagler, Arnon ^o   Petrucci, Maria T ^e   Hajek, Roman ^p   Pezzatti, Sara ^g   Delforge, Michel ^q   Patriarca, Francesca ^a   Donato, Francesca ^a,h   Cerrato, Chiara ^a   Nozzoli, Chiara ⁱ   Yu, Zhinuan ^r   Boccadifuoco, Luana ^a   Caravita, Tommaso ^f   Benevolo, Giulia ^b   Guglielmelli, Tommasina ^a   Vincelli, Donatella ^j   Jacques, Christian ^r   Dimopoulos, Meletios A ^s   Ciccone, Giovannino ^c   Musto, Pellegrino ^k   Corradini, Paolo ^l   Cavo, Michele ^m   Boccadoro, Mario ^a   more..

^a UNIVERSITY OF TURIN   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f S EUGENIO HOSPITAL   (Italy)

^g SAN GERARDO HOSPITAL   (Italy)

^h UNIVERSITY HOSPITAL OF UDINE   (Italy)

ⁱ CAREGGI UNIVERSITY HOSPITAL   (Italy)

^j BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

^k REFERRAL CANCER CENTER OF BASILICATA   (Italy)

^l UNIVERSITY OF MILAN   (Italy)

^m UNIVERSITY OF BOLOGNA   (Italy)

ⁿ MEIR MEDICAL CENTER   (Israel)

^o TEL AVIV UNIVERSITY   (Israel)

^p UNIVERSITY HOSPITAL OSTRAVA   (Czech Republic)

^q UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^r CELGENE CORPORATION   (United States)

^s UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; LENALIDOMIDE; THALIDOMIDE; ANTINEOPLASTIC AGENT; DEXAMETHASONE; MELPHALAN; PREDNISONE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CONTINUOUS THERAPY; FEMALE; FIXED DURATION OF THERAPY; FOLLOW UP; HUMAN; INTENTION TO TREAT ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); POST TREATMENT SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORTEZOMIB; DEXAMETHASONE; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDNISONE; THALIDOMIDE;

EID: 84945208372     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.60.2466     Document Type: Article

References (30)

1. Howlader N, Noone AM, Krapcho M, et al: SEER cancer statistics review, 1975-2010. Bethesda, MD, National Cancer Institute, based on November 2012 SEER data submission, posted to the SEER Web site, 2013. http://seer.cancer.gov/csr/1975-2010/
2. Fayers PM, Palumbo A, Hulin C, et al: Thalidomide for previously untreated elderly patients with multiple myeloma: Meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood 118:1239-1247, 2011
3. San Miguel JF, Schlag R, Khuageva NK, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 359:906-917, 2008
4. Mateos MV, Richardson PG, Schlag R, et al: Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: Updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259-2266, 2010
5. Palumbo A, Cavallo F: Have drug combinations supplanted stem cell transplantation in myeloma? Hematology Am Soc Hematol Educ Program 2012:335-341, 2012
6. Ludwig H, Durie BG, McCarthy P, et al: IMWG consensus on maintenance therapy in multiple myeloma. Blood 119:3003-3015, 2012
7. Palumbo A, Hajek R, Delforge M, et al: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med 366:1759-1769, 2012
8. Palumbo A, Bringhen S, Rossi D, et al: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol 28:5101-5109, 2010
9. Palumbo A, Bringhen S, Larocca A, et al: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: Updated follow-up and improved survival. J Clin Oncol 32: 634-640, 2014
10. Benboubker L, Dimopoulos MA, Dispenzieri A, et al: Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med 371:906-917, 2014
11. McCarthy PL, Owzar K, Hofmeister CC, et al: Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1770-1781, 2012
12. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. N Engl J Med 366:1782-1791, 2012
13. Attal M, Lauwers-Cances V, Marit G, et al: Lenalidomide maintenance after stem-cell transplantation for multiple myeloma: Follow-up analysis of the IFM 2005-02 trial. Blood 122:21 2013 (abstr 406)
14. Palumbo A, Cavallo F, Gay F, et al: Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med 371:895-905, 2014
15. European Medicines Agency: Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2013/01/WC500137126.pdf
16. Durie BG, Harousseau JL, Miguel JS, et al: International uniform response criteria for multiple myeloma. Leukemia 20:1467-1473, 2006
17. Bladé J, Samson D, Reece D, et al: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation: Myeloma Subcommittee of the EBMT, European Group for Blood and Marrow Transplant. Br J Haematol 102:1115-1123, 1998
18. Dimopoulos MA, Petrucci MT, Foà R, et al: PFS2 in elderly patients with newly diagnosed multiple myeloma (NDMM): Results from the MM-015 study. Blood 122:21 2013 (abstr 405)
19. Palumbo A, Bringhen S, Liberati AM, et al: Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: Updated results of a randomized controlled trial. Blood 112: 3107-3114, 2008
20. Wijermans P, Schaafsma M, Termorshuizen F, et al: Phase III study of the value of thalidomide added to melphalan plus prednisone in elderly patients with newly diagnosed multiple myeloma: The HOVON 49 Study. J Clin Oncol 28:3160-3166, 2010
21. Morgan GJ, Gregory WM, Davies FE, et al: The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis. Blood 119:7-15, 2012
22. Barlogie B, Pineda-Roman M, van Rhee F, et al: Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities. Blood 112:3115-3121, 2008
23. Spencer A, Prince HM, Roberts AW, et al: Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure. J Clin Oncol 27:1788-1793, 2009
24. Attal M, Harousseau JL, Leyvraz S, et al: Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 108:3289-3294, 2006
25. Stewart AK, Trudel S, Bahlis NJ, et al: A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: The National Cancer Institute of Canada Clinical Trials Group Myeloma 10 Trial. Blood 121:1517-1523, 2013
26. Traer E, Deininger MW: How much and how long: Tyrosine kinase inhibitor therapy in chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 10:S20-S26, 2010 (suppl 1)
27. Morgan GJ, Davies FE, Gregory WM, et al: Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results. Haematologica 97:442-450, 2012
28. Waage A, Gimsing P, Fayers P, et al: Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma. Blood 116:1405-1411, 2010
29. Ye X, Huang J, Pan Q, et al: Maintenance therapy with immunomodulatory drugs after autologous stem cell transplantation in patients with multiple myeloma: A meta-analysis of randomized controlled trials. PLoS One 8:e72635, 2013
30. Kagoya Y, Nannya Y, Kurokawa M: Thalidomide maintenance therapy for patients with multiple myeloma: Meta-analysis. Leuk Res 36:1016-1021, 2012